chevron_leftBack
As of 5 June 2026, Nanobiotix S.A. has a market cap of $1.59B USD, ranking #8149 globally and #126 in France.
It ranks #682 in the Healthcare sector, and #262 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$1.59BUSD
1.37B EUR
Enterprise Value
$1.65BUSD
1.42B EUR
Revenue (TTM)
$37.8MUSD
32.59M EUR
EBITDA (TTM)
-$12.18MUSD
-10.49M EUR
Net Income (TTM)
-$27.79MUSD
-23.96M EUR
EBITDA Margin
-32%
Profit Margin
-74%
PS Ratio
42.2
PB Ratio
-16.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Laurent Levy
open_in_new
Employees
103
Founded
2003
Website
nanobiotix.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.4% | 5.3% | 7.3% | 56% | 84% | 900% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NANO
Nanobiotix SA
ISIN: FR0011341205
Shares Out.:
Shares Outstanding:
50.597M1
Shares Float:
48.432M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
28.24 EUR | |
|
0QAV
Nanobiotix SA
ISIN: FR0011341205
|
27.90 EUR | |
|
NASDAQ
MIC: XNAS
|
NBTX
Nanobiotix SA ADR
ISIN: US63009J1079
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
33.20 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EPA: SAN
|
$110.49B
7K%
95.26B EUR
|
19.9
|
|
EPA: IPN
|
$15.75B
888%
13.58B EUR
|
31.1
|
|
EPA: DBV
|
$1.24B
-22%
1.07B EUR
|
-
|
|
EPA: VETO
|
$1.1B
-31%
949.55M EUR
|
16.6
|
|
EPA: MEDCL
|
$951.96M
-40%
820.77M EUR
|
-
|
|
EPA: ALCLS
|
$288.79M
-82%
248.99M EUR
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
48K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
34K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
23K%
|
97.4
|
|
SIX: RO
|
$323.4B
20K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.25B
18K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$276.26B
17K%
218.9B CHF
|
20.5
|
chevron_leftBack